GSK 2831781

Drug Profile

GSK 2831781

Alternative Names: GSK2831781; IMP-731

Latest Information Update: 29 Aug 2016

Price : $50

At a glance

  • Originator Immutep
  • Developer GlaxoSmithKline
  • Class Antipsoriatics; Monoclonal antibodies
  • Mechanism of Action Cytotoxic T lymphocyte inhibitors; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Plaque psoriasis

Most Recent Events

  • 24 Aug 2016 Prima BioMed has patent protection for GSK 2831781 in Europe .
  • 02 Aug 2016 GSK plans a phase II for Autoimmune diseases
  • 02 Mar 2015 GSK 2831781 is covered by patent protection in Canada, China, Europe, Japan, Australia, and USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top